“Latest Treatments for Pulmonary Fibrosis: Pharmacological Effects and Therapeutic Outcomes”
Arata Azuma , Japan
Abstract:
This article provides an overview of the development of treatments for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). As existing therapies—such as pirfenidone and nintedanib—do not always yield sufficient efficacy, the development of nerandomilast was pursued with the expectation of providing additional therapeutic benefit. Findings suggest that this approach may not only inhibit the decline in forced vital capacity (FVC) but also extend patient survival.
Meanwhile, research into TAS-115 failed to demonstrate the intended therapeutic effect. Currently, investigations targeting LPA1 and PDE5 inhibition are also underway.
Efforts to develop therapeutic agents with distinct mechanisms of action continue, with careful evaluation of whether their adverse event profiles remain within an acceptable range compared to existing treatments.
The ultimate goal is to halt the deterioration of respiratory function and improve patient survival.